Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors-Reference-Cited by-同舟云学术

Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors

Published:2022-02-22 Issue:1 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Park Seung Bum¹^ORCID,Irvin Parker¹,Hu Zongyi¹,Khan Mohsin¹,Hu Xin²,Zeng Qiru³,Chen Catherine²,Xu Miao²,Leek Madeleine¹,Zang Ruochen³,Case James Brett⁴^ORCID,Zheng Wei²^ORCID,Ding Siyuan³^ORCID,Liang T. Jake¹^ORCID

Affiliation:

1. Liver Diseases Branch, NIDDK, NIH, Bethesda, Maryland, USA

2. Division of Pre-Clinical Innovations, NCATS, NIH, Rockville, Maryland, USA

3. Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA

4. Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

Abstract

SARS-CoV-2 is an enveloped virus that requires membrane fusion for entry into host cells. Since the fusion process is relatively conserved among enveloped viruses, we tested our HCV fusion inhibitors, dichlorcyclizine and fluoxazolevir, against SARS-CoV-2.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.03238-21

Reference64 articles.

1. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

2. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

3. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses